MARKET

CALA

CALA

Calithera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.780
+0.080
+2.96%
Opening 10:55 03/08 EST
OPEN
2.720
PREV CLOSE
2.700
HIGH
2.820
LOW
2.660
VOLUME
272.28K
TURNOVER
--
52 WEEK HIGH
8.18
52 WEEK LOW
2.384
MARKET CAP
196.15M
P/E (TTM)
-2.0024
1D
5D
1M
3M
1Y
5Y
Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference
SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-t...
GlobeNewswire · 6d ago
Relapsed Acute Myeloid Leukemia Drug Market Global Potential Growth, Share, Demand and Analysis of Key Players - Forecasts to 2020 -2027 By Ameco Research
pune, India, Tue, 23 Feb 2021 02:01:02 / Comserve Inc. / -- Relapsed Acute Myeloid Leukemia Drug market is segmented by Type, and by Application. Players,...
Comserve · 02/23 07:03
Gastrointestinal Stromal Tumor (GIST) Drug Market Size, Share, Growth 2021 with Forecast,Global Organizations, Top Vendors, Industry Research,Market and End User By 2026
Feb 22, 2021 (The Expresswire) -- Global Gastrointestinal Stromal Tumor (GIST) Drug Market 2021 industry research report gives Advancement strategies and...
The Express Wire · 02/23 04:49
Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-th...
GlobeNewswire · 02/22 12:00
Relapsed Acute Myeloid Leukemia Drug Market 2021 Industry Manufactures Strategy Analysis, Share Estimation, Product Types, Applications, Trends and Forecast 2027
Feb 17, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Relapsed Acute Myeloid...
The Express Wire · 02/17 05:24
Gastrointestinal Stromal Tumor (GIST) Drug Market 2021 Growing Trends in Global Regions with Industry Analysis, Growth Size, Share, Types, Applications, Development Strategy and Forecast till 2027
The Express Wire · 02/15 05:15
Waldenstrom Macroglobulinemia Therapeutics Market Size By Analysis, Industry Share, Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, and Forecasts to 2026
Feb 11, 2021 (The Expresswire) -- Global "Waldenstrom Macroglobulinemia Therapeutics Market" research report would be to deliver the correct and tactical...
The Express Wire · 02/11 05:53
Relapsed Acute Myeloid Leukemia Drug Market Size Research Report 2021 by Growth Rate, Revenue Estimates, Market Dynamics, Industry Trends and Forecast to 2027 Says Absolute Reports
Feb 08, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Relapsed Acute Myeloid Leukemia Drug...
The Express Wire · 02/08 10:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CALA. Analyze the recent business situations of Calithera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CALA stock price target is 5.00 with a high estimate of 10.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 61.85M
% Owned: 87.66%
Shares Outstanding: 70.56M
TypeInstitutionsShares
Increased
30
1.72M
New
44
2.64M
Decreased
34
5.54M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.22%
Pharmaceuticals & Medical Research
+1.05%
Key Executives
President/Chief Executive Officer/Co-Founder/Director
Susan Molineaux
Chief Financial Officer/Chief Accounting Officer/Secretary
Stephanie Wong
Senior Vice President/Chief Compliance Officer/General Counsel
Sumita Ray
Senior Vice President
Christopher Molineaux
Senior Vice President
Eric Sjogren
Vice President
Francesco Parlati
Other
Curtis Hecht
Other
Keith Orford
Lead Director/Independent Director
Deepika Pakianathan
Lead Director/Independent Director
Deepa Pakianathan
Independent Director
Sunil Agarwal
Independent Director
Jonathan Drachman
Independent Director
Scott Garland
Independent Director
Jean George
Independent Director
Suzy Jones
Independent Director
Blake Wise
Independent Director
H. Ward Wolff
No Data
About CALA
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Webull offers kinds of Calithera Biosciences Inc stock information, including NASDAQ:CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CALA stock methods without spending real money on the virtual paper trading platform.